Lilly's weight-loss drug shows promise

Eli Lilly's experimental drug, retatrutide, has demonstrated significant positive results in clinical trials, meeting key endpoints for both weight loss and blood sugar reduction. This development marks a notable advancement in the pharmaceutical sector's efforts to address metabolic health challenges. The drug's efficacy suggests a potential new therapeutic option for individuals struggling with weight management and related conditions, pending further regulatory review and approval.